Hutchmed China Limited (HCM) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Suppliers, else..
 
Hutchmed china Limited  (NASDAQ: HCM)
 

Hutchmed China Limited Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HCM Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q4 MRQ) -12.96 % 7.99 % 8.07 % 9.17 %
Q / Q Revenue Growth (Q4 MRQ) - 1.44 % 1.81 % 4.22 %
Y / Y Revenue Growth (for 12 months ending Q4 TTM) -12.96 % 7.47 % 7.04 % %
Sequential Revenue Growth (for 12 months ending Q4 TTM) - 4.22 % 3.51 % 2.08 %
Revenue 5 Year Average Growth 19.2 % 7.41 % 8.65 % 10.59 %


HCM's Growth Comparisons in IV. Quarter 2025




Hutchmed China Limited reported sharp sales fall by -12.96% from the same quarter a year ago, in the fourth quarter 2025, despite the rising Revenue in Major Pharmaceutical Preparations industry by 7.99%, and underperformed the 8.07% Revenue growth in the Healthcare sector. Weak fourth quarter sales, in Major Pharmaceutical Preparations industry and within the Healthcare sector, were reflected in Hutchmed China Limited results which underperformed overall market.

Sequentially company's Revenue were unchanged from the third quarter results. . Looking into annual growth, sales grew by 19.2% on average in last five years, while S & P 500's including only Businesses with the fourth quarter 2025 earnings reports, average yearly sales growth is 10.59%.

HCM Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Third parties
-
-
Related parties
-
-
Invoiced Goods-Marketed Products
-
-
Invoiced Goods-Distribution
-
-
Services-Commercialization of Marketed Products
-
-
Services-Commercialization of Marketed Products Third parties
-
-
License Collaborations-Services
-
-
License Collaborations-Services Third parties
-
-
License Collaborations-Royalties
-
-
License Collaborations-Royalties Third parties
-
-
License Collaborations-Licensing
-
-
License Collaborations-Licensing Third parties
-
-
License Collaborations-Manufacturing supply
-
-
Oncology Immunology segment
-
-
Oncology Immunology Third parties
-
-
Oncology Immunology Invoiced Goods-Marketed Products
-
-
Oncology Immunology Services-Commercialization of Marketed Products
-
-
Oncology Immunology License Collaborations-Services
-
-
Oncology Immunology License Collaborations-Royalties
-
-
Oncology Immunology License Collaborations-Licensing
-
-
Oncology Immunology License Collaborations-Manufacturing supply
-
-
Other Ventures segment
-
-
Other Ventures Third parties
-
-
Other Ventures Related parties
-
-
Other Ventures Invoiced Goods-Distribution
-
-
Reportable Oncology Immunology segment
-
-
Reportable Oncology Immunology R D
-
-
Reportable Oncology Immunology Marketed Products
-
-
Reportable Other Ventures segment
-
-
PRC
-
-
US and others
-
-
Customer A
-
-
Customer B
-
-
Total
-
-


Growth Rates of HCM's Income in the fourth quarter 2025


HCM Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q4 MRQ) - 53.67 % 27.58 % 29.95 %
Sequential Operating Income Change (Q4 MRQ) - -27.23 % -17.34 % 4.5 %
Y / Y Operating Income Growth (Q4 TTM) - 48 % 37.03 % 14.37 %
Sequential Operating Income Growth (Q4 TTM) - 13.44 % 9.74 % 6.96 %
Operating Income 5 Year Avg. Change - 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q4 MRQ) 1099.19 % - - 21.83 %
Sequential Income from Cont. Ops. Change (Q4 MRQ) - - - 11.13 %
Y / Y Income from Cont. Ops. Change (Q4 TTM) 1099.19 % -59.4 % -25.13 % 16.46 %
Sequential Income from Cont. Ops. Change (Q4 TTM) 1099.19 % -10.61 % -6.43 % 6.05 %
Income from Cont. Ops. 5 Year Avg. Change - -0.55 % 0.17 % -28.52 %

HCM Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q4 MRQ) 1099.19 % -26.27 % 16.75 % 21.56 %
Q / Q Net Income Growth (Q4 MRQ) - -43.4 % -34.6 % 11.12 %
Y / Y Net Income Change (Q4 TTM) 1099.19 % 27.23 % 32.74 % 16.59 %
Sequential Net Income Change (Q4 TTM) 1099.19 % 3.41 % 7.31 % 6.03 %
Net Income 5 Year Avg. Growth - 14.55 % 9.21 % 22.96 %

HCM's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q4 MRQ) 1225 % - - 21.83 %
Sequential EPS from Cont. Ops. Change (Q4 MRQ) - - - 11.13 %
Y / Y EPS from Cont. Ops. Change (Q4 TTM) 1225 % - - -
Sequential EPS from Cont. Ops. Change (Q4 TTM) 1225 % - - -99.7 %
EPS from Cont. Ops. 5 Year Avg. Growth - -10.78 % 0.17 % -28.52 %



HCM EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q4 MRQ) 1200 % -29.53 % 16.75 % -28.52 %
Q / Q EPS Net Growth (Q4 MRQ) - -32.44 % -34.6 % 11.12 %
Y / Y EPS Net Change (for 12 months ending Q4 TTM) - - - -99.97 %
Sequential EPS Net Change (for 12 months ending Q4 TTM) 1200 % - - -99.87 %
EPS Net 5 Year Avg. Change - 14.55 % 9.21 % 22.96 %



Despite the -29.53% decline in Major Pharmaceutical Preparations industry, Hutchmed China Limited showed impressive surge in EPS in the fourth quarter by 1200% from the same quarter a year ago, to $0.52, Healthcare sector improved 16.75%. Despite modest earnings per share in the Major Pharmaceutical Preparations industry and ind the Healthcare sector, Hutchmed China Limited reported above average market earnings per share growth.

Sequentially company's EPS were unchanged from the third quarter results. . Looking into annual growth, income per share grew by 19.2% on average in the last five years, while the S & P 500's including only the businesses with the fourth quarter 2025 financial results, average yearly income per share growth is 22.96%.

HCM Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q4 MRQ) - -15.03 % -10.43 % 2 %
Sequential Free Cash Flow Change (Q4 MRQ) - -44.18 % -28.82 % 22.32 %
Y / Y Free Cash Flow Change (Q4 TTM) - 9.6 % 11.09 % 11.81 %
Sequential Free Cash Flow Change (Q4 TTM) - 1.75 % 1.93 % 2.41 %
Free Cash Flow 5 Year Avg. Change - 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q4 MRQ) - - -90.24 % 1035.72 %
Sequential Net Cash Flow Change (Q4 MRQ) - - -99.01 % -
Y / Y Net Cash Flow Change (Q4 TTM) - -21.47 % -23.28 % -
Sequential Net Cash Flow Change (Q4 TTM) - -44.21 % -25.11 % -
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q4 MRQ) -44.24 % 19.29 % 9.45 % 23.41 %
Sequential Capital Expenditures Change (Q4 MRQ) - 20.61 % 18.78 % 18.97 %
Y / Y Capital Expenditures Change (Q4 TTM) -44.24 % 20.54 % 10.57 % 23.88 %
Sequential Capital Expenditures Change (Q4 TTM) -44.24 % 11.3 % 6.56 % 7.02 %
Capital Expenditures 5 Year Avg. Change 24.89 % 8.82 % 9.12 % 14.73 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.